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Interstitial lung disease in children (chILD) is rare, and
most centres will only see a few cases/year. There are
numerous possible underlying diagnoses, with specific
and non-specific treatment possibilities. The chILD-EU
collaboration has brought together centres from across
Europe to advance understanding of these
considerations, and as part of this process, has created
standard operating procedures and protocols for the
investigation of chILD. Where established consensus
documents exist already, for example, for the
performance of bronchoalveolar lavage and processing of
lung biopsies, these have been adopted. This manuscript
reports our proposals for a staged investigation of chILD,
starting from when the condition is suspected to
defining the diagnosis, using pathways dependent on
the clinical condition and the degree of illness of the
child. These include the performance of genetic testing,
echocardiography, high-resolution CT, bronchoscopy
when appropriate and the definitive investigation of lung
biopsy, in order to establish a precise diagnosis. Since no
randomised controlled trials of treatment have ever been
performed, we also report a Delphi consensus process to
try to harmonise treatment protocols such as the use of
intravenous and oral corticosteroids, and add-on
therapies such as hydroxychloroquine and azithromycin.
The aim is not to dictate to clinicians when a therapeutic
trial should be performed, but to offer the possibility to
collaborators of having a unified approach when a
decision to treat has been made.
INTRODUCTION
Interstitial lung disease in children (chILD) is rare;
there are no reliable estimates, but prevalence is
likely <1 per 100 000, as against 60–80 per
100 000 in adults;1 the average European Hospital
will see no more than 5 cases/year.2 chILD is more
diverse than interstitial lung disease in adults, com-
prising more than 200 different conditions with a
variety of proposed classifications.3–6 Since individ-
ual centres see so few chILD patients, it is unsur-
prising that there are no randomised controlled
trials of treatment. To address this, a proposal was
funded by the European Union FP7 stream7 to (a)
create a pan-European registry; (b) peer review all
potential chILD diagnoses; (c) gather prospective
longitudinal data from well-defined groups of chil-
dren, including the results of N of 1 therapeutic
trials; (d) set up and perform the first randomised
controlled trials of chILD treatment. In order to
achieve this, it was essential that the diagnostic
approaches and treatment protocols were harmo-
nised across Europe. This manuscript reports on
our agreed approach, including standard operating
protocols, and the Delphi consensus process used
to harmonise our approach to treatment, across the
entire childhood age range. The reader is also
referred to an official American Thoracic Society
statement, which covers only the 0–2 years age
range.8 The aim is not to dictate to clinicians
whether to undertake trials of particular treatments
but to encourage and enable the use of the same
protocol for treatments where there is no evidence.
THE STARTING POINT: WHEN TO SUSPECT
CHILD—TYPICAL PRESENTATIONS
Shortly after birth
The earliest presentation of chILD is shortly after
birth, with unexplained respiratory distress in a
term baby. This frequently and rapidly proceeds to
intubation and ventilation, with relentlessly pro-
gressive respiratory failure8 9 leading to death or
lung transplantation, if the latter is available. The
usual causes are surfactant protein gene muta-
tions9 10 and the alveolar-capillary dysplasia spec-
trum;11 some of the former may make a partial
recovery10 and the baby may survive in chronic
respiratory failure. The same conditions should be
considered in preterm babies with respiratory dis-
tress which does not run the normal clinical
course, but the yield of positive results is much less.
First 2 years of life
Later presentations of chILD are very non-specific.
In the first 2 years of life, symptoms in descending
order of frequency are fast breathing, failure to
thrive, typically dry cough and wheeze (this last in
25% of cases) in the absence of respiratory tract
infection.3 Suggested protocols for the clinical
assessment of these infants are available on the
chILD-EU website (http://www.klinikum.uni-
muenchen.de/Child-EU/en/index.html). SpC muta-
tions may present as respiratory syncytial virus
(RSV)-positive bronchiolitis, which fails to
resolve;12 there is animal evidence that RSV causes
increased inflammation and worse outcomes in
animals with SpC mutations.13 14 Signs of chILD
include hypoxia, tachypnoea, recession, crackles,
pulmonary hypertension and gastro-oesophageal
reflux.3 Auscultation can be normal in more than a
third. Chest deformity, particularly pectus excava-
tum, has been reported especially with ABCA3
mutations.15
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2–16 years of age
There are no large series from this age group, but it is likely that
the clinical picture will not be dissimilar. In older children,
exercise-induced breathlessness may be the presentation,
although other, commoner causes need to be considered.
The USA group have coined the term ‘chILD syndrome’7
which is a label mandating further evaluation in a child with
diffuse lung disease who has had common causes excluded (eg,
cystic fibrosis, uncoordinated swallow leading to aspiration) and
who has at least three of four criteria, namely (a) respiratory
symptoms; (b) respiratory signs, including digital clubbing and
failure to thrive; (c) hypoxaemia; and (d) diffuse radiological
changes. Clearly, another important part of the initial work-up
is a full clinical evaluation of the child, looking for signs of a
systemic disease (especially renal, skin, liver, eyes, joints), evi-
dence of pulmonary hypertension and signs of reflux and
aspiration.
In all cases, a careful history is mandated, including a family
history, which may lead to suspicion of genetic causes of chILD,
and environmental exposures if there is any possibility of hyper-
sensitivity pneumonitis; the recent outbreak of ILD in adults
and children in Korea emphasises the importance of the envir-
onmental history.16–18 Simple laboratory testing may give clues
to the diagnosis. Anaemia and reticulocytosis are seen in pul-
monary haemorrhagic syndromes. Peripheral eosinophilia sug-
gests parasitic disease, hypersensitivity, eosinophilic lung disease
and systemic eosinophilic diseases. Stool occult blood results
may be positive in patients with pulmonary haemorrhage;
indeed these children may have undergone extensive diagnostic
work-up for iron deficiency without the possibility of pulmon-
ary haemorrhage having been considered.19
INITIAL INVESTIGATIONS
Given the non-specific nature of the presentation of chILD the
probability of a diagnosis can be enhanced by structured investi-
gation. A simple severity score has been proposed (table 1),20
which sadly has yet to be superseded by more sophisticated
biomarkers:
1. Clinical: Evidence of hypoxaemia is often the first abnormal-
ity to raise concern and should be noted whether it is
present at rest both awake and asleep breathing room air. In
older children exercise testing should be used to unmask
desaturation which is not present at rest, following standard
protocols; there is insufficient evidence to recommend a par-
ticular method over others. It is unwise and uninformative
to exercise a child who is desaturated at rest, without giving
supplemental oxygen.
2. Radiology: The chest radiograph may be normal, but more
likely reveals non-specific abnormalities. Gastro-oesophageal
reflux is common in young children and also in patients with
respiratory disease; deciding if reflux may be contributory is
difficult even in the presence of a barium swallow reflux
study and a pH study.
3. Physiological testing: Lung function testing in infants has
little general availability and the role in infants is unclear.
Neuroendocrine cell hyperplasia of infancy (NEHI) is char-
acterised by a pattern of hyperinflation and airflow obstruc-
tion,21 but there is insufficient experience to rely on
physiological patterns in infancy in chILD. In older children,
the usual pattern is classically restrictive, with a reduced
FEV1 and FVC, a normal or even elevated FEV1/FVC ratio
and reduced lung volumes. Carbon monoxide transfer (dif-
fusing capacity or transfer factor of the lung for carbon
monoxide, DLCO) is usually reduced, and if elevated, pul-
monary haemorrhage should be suspected.22 The occasional
chILD may have a more obstructive pattern of physiology.
4. Echocardiogram: Should be an early investigation to estimate
pulmonary artery pressure, and exclude cardiac mimics of
interstitial lung disease, such as cor triatrium leading to pul-
monary oedema.23 Pulmonary hypertension, where present,
should be diagnosed and treated accordingly in liaison with
paediatric cardiology colleagues.
5. Blood studies: A focused approach is recommended. Tests
can be grouped into (a) genetic abnormalities; (b) immune
function (especially if the follicular bronchiolitis-lymphoid
interstitial pneumonia spectrum is suspected); (c) auto-
antibody studies (cases of pulmonary haemorrhage, alveolar
proteinosis, or if there is evidence of a systemic disease); (d)
environmental organic dust exposures (hypersensitivity
pneumonitis); (e) miscellaneous, that is, ACE inhibitors in
cases of suspected sarcoidosis. Note that novel genetic
chILD entities with multisystem disease are being
described,24 25 and the younger the child is the more care-
fully new or established genetic diagnoses are sought. In all
cases of chILD, DNA of the patient and parents should be
stored for future analyses. The clinical situation will dictate
which tests are performed, and whether it is realistic to
await results before proceeding to a CTor lung biopsy.
A proposed diagnostic pathway is shown in figure 1. In terms
of timing of enrolment of suspected chILD patients in the regis-
try, a preliminary discussion at an early stage would be valuable
for the patient. The use of, for example, standardised scanning
protocols is to be preferred.
IF CHILD IS SUSPECTED CLINICALLY: THE ROLE OF CHEST
CT SCANNING
CT chest is invariably performed in the investigation of a pos-
sible case of ChILD. The purpose of chest CT is to evaluate the
presence and extent of disease. In some cases it can be diagnos-
tic,26 but is more usually supportive of a diagnosis that takes
account of clinical history, blood results and sometimes bronch-
oalveolar lavage and/or biopsy material.
CT scanning for chILD should only be performed in centres
experienced in paediatric radiology. The general principles of
scanning are to minimise radiation dosage to the child while
maximising the information obtained; a very low dose scan
which is diagnostically useless benefits no one.27 Detailed proto-
cols for reducing radiation exposure while maintaining image
quality are given online, and these should be audited regularly.
The optimal CT scan is a volumetric scan during inspiration,
performed in tandem with a high-resolution CT (HRCT)
fine-cut spaced expiratory scan. Ventilation should be controlled
to ensure satisfactory, interpretable, scan output. In young chil-
dren this necessitates a general anaesthetic (ie, under 5 years of
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2 Yes No No No
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age), although some centres advocate sedation and controlled,
bag and mask ventilation.28 As always, the risk of anaesthesia or
sedation should be weighed against the risk of not obtaining
diagnostic information. Older children should be able to reliably
hold breath in inspiration and expiration for 6–10 s. In children
who are ventilated under a general anaesthetic it is important to
attain appropriate ventilation pressures in both inspiration and
expiration; these details are provided in our online standard
operating procedure (SOP).
The administration of contrast medium will make the assess-
ment of ground glass shadowing almost impossible, and so
careful consideration should be given as to the risk/benefit of
using a contrast medium based on the anticipated diagnosis.
The need to assess the pulmonary vasculature will require the
use of contrast, with detrimental effects on the interpretation of
some lung components.
The three outcomes of HRCT scanning (figure 1) are (1)
chILD unlikely including that the CT is normal. Although a
normal CT scan is unusual in ChILD, it may occur in some
cases early in the course of the disease process where there are
very few non-diagnostic CT features; (2) chILD present and a
specific diagnosis can be made26; and (3) chILD present, with
or without possible evidence of a comorbidity such as aspiration
(eg, consolidation in a typical distribution), but a specific diag-
nosis cannot be made. If chILD is unlikely then appropriate
diagnostic algorithms to investigate possible non-chILD findings
are deployed; these are beyond the scope of this article. A spe-
cific diagnosis of chILD may allow immediate action; however,
the ability for CT to be completely diagnostic is limited to rela-
tively few conditions (ie, pulmonary alveolar proteinosis, extrin-
sic allergic alveolitis and NEHI), and these too are usually
supported by other diagnostic tests, that is, environmental aller-
gen and prednisolone response in hypersensitivity pneumonitis
(figure 2A) ,or granulocyte-macrophage colony-stimulating fac-
torreceptor auto-antibody or gene mutation studies, surfactant
protein gene mutations and an immunological work-up in cases
of pulmonary alveolar proteinosis (figure 2B).
It is recognised that although faster CT scanners may enable
chest CT without the need for anaesthetic, we do not recom-
mend this unless anaesthesia is thought to be unsafe, as (1) the
technique frequently provides suboptimal results from
respiratory movements made by the child and (2) the variance
in lung volumes during an uncontrolled respiratory cycle will
reduce the value of the scans obtained and the reliability of CT
to provide the supportive evidence for a diagnosis of ChILD.
Whatever the timing of investigations, planning to avoid the
child having multiple general anaesthetics is essential. So fibre-
optic bronchoscopy should only be done as a separate procedure
if it is likely to be diagnostic; otherwise, it is better performed
under the same anaesthetic as the lung biopsy.
INVASIVE TESTING: FLEXIBLE BRONCHOSCOPY
Bronchoscopy with bronchoalveolar lavage (BAL) may be diag-
nostic in pulmonary haemorrhage syndromes, alveolar proteino-
sis and eosinophilic lung disease, and a normal cell differential
can rule out hypersensitivity pneumonitis. BAL target site
should be chosen on the basis of radiological abnormality or
airway inspection. If BAL is to be performed during the same
anaesthetic as CT, then it should follow the imaging; where it is
to be performed at the time of lung biopsy, the lobe designated
for a lung biopsy should be avoided. Where possible flexible
bronchoscopy should be performed via endotracheal or laryn-
geal mask to reduce suction channel contamination from the
upper airway. BAL volume is adjusted to body weight using
3 mL/kg of sterile normal saline divided into three equal frac-
tions in children weighing <20 kg and 3 mL/kg in 20 mL por-
tions in children weighing >20 kg.29 Negative suction pressure
should be adjusted to avoid visible airway collapse. The first
bronchoalveolar lavage fluid aliquot should be unfiltered and
used for microbiological studies, and the other aliquots should
be pooled (unless one is bloodstained), filtered through sterile
gauze only if a lot of mucus is present, which is unlikely in
chILD, and used for analysis of cellular and non-cellular compo-
nents. Transport and preparation of samples is provided in our
online SOP. Clinicians should liaise with their laboratories to
ensure appropriate investigation of samples, to include appropri-
ate microbiological analysis and culture (bacterial, fungal, virus),
Oil Red O staining (fat-laden macrophages), periodic acid–
Schiff staining (pulmonary alveolar proteinosis) and iron
staining (ie, Prussian blue for haemosiderin within macrophages)
to diagnose pulmonary haemorrhage syndrome. CD1a-positive
cells are consistent with Langerhans cell histiocytosis. A
Figure 1 Proposed flow chart for investigating interstitial lung disease in children (chILD). If the child is well and stable, progress to the more
invasive investigations may not be indicated. HRCT, high-resolution CT.
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lymphocyte-predominant BAL with an elevated CD4/CD8 ratio
(>2) suggests sarcoidosis with involvement of the lung.30
Metabolic abnormalities may be diagnosed by BAL, for
example, sea-blue macrophages.31
Endobronchial (EBx) and transbronchial (TBB) biopsies are
rarely performed in ChILD and are not recommended unless a
specific diagnosis that could be made by these techniques is sus-
pected. Specific conditions such as pulmonary alveolar micro-
lithiasis may be diagnosed by TBB,32 but the samples are too
small to diagnose most chILDs. Blind EBx may detect sarcoid
granulomas,33 but is not useful for diagnosing NEHI.34 Our
protocols for these procedures can be found online if needed.
INVASIVE TESTING: SURGICAL LUNG BIOPSY
The timing and need for lung biopsy is controversial. chILD
patients who are well and thriving may not merit biopsy even
if the CT scan appearances are not typical. Some would con-
sider that an oxygen requirement warrants a diagnostic lung
biopsy, while others would wait and see. There is clearly merit
in performing an invasive procedure only if treatment will be
changed as a result. Steroids are a mainstay of treatment for
chILD and the timing of biopsy related to their initiation is
often dictated by circumstance. Where possible, biopsy prior
to steroid treatment is recommended (to minimise risk to
wound healing and to expedite specific chILD treatments, ie,
TNF-α antagonist infliximab combined with methotrexate for
sarcoidosis, and cyclophosphamide for angiitis with granulo-
matosis). The dilemma posed by the sick patient with chILD
who is on the verge of ventilation (and biopsy would most
likely tip to requiring ventilation) or is unstable on a ventilator
often dictates that a steroid trial before a biopsy may be
appropriate. If the child is already ventilated, unless the venti-
latory requirements are very high, a biopsy can safely be
performed.
The site of biopsy should be guided by a recent CT chest.
There should be liaison between the surgeon, pathologist and
paediatrician. Any other procedures which may merit general
anaesthesia (eg, bronchoalveolar lavage, mucosal biopsy, place-
ment of a vascular access device or gastrostomy) should be care-
fully planned. The tip of the middle lobe and lingula should be
avoided, and biopsy should preferably be from two sites, and
sample areas of varying disease severity. Increasingly, biopsy is
using video-assisted thoracoscopic surgery rather than a mini-
thoracotomy. Whatever technique is used, the procedure must
only be undertaken by an experienced surgeon, who is confident
of obtaining adequate biopsies (at least 10×10×10 mm); a very
superficial biopsy, which does not contain distal airways, may
result in diagnostic error.
Figure 2 Diagnostic high-resolution CTs (HRCTs) in childhood interstitial lung disease (chILD). (A) There is diffuse ground glass shadowing with a
widespread soft centrilobular nodular pattern. This is virtually diagnostic of hypersensitivity pneumonitis, in this case due to pet doves. (B) There is
generalised ground glass opacification with thickening of the interlobular septa, giving the classical cobblestone appearance of pulmonary alveolar
proteinosis. It is not possible to distinguish the different aetiologies from the HRCT appearances.
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Samples should be rapidly transported to a waiting patholo-
gist working in an accredited laboratory working to inter-
national standards.35 There should be access to light microscopy
and common special stains, immunohistochemistry, genetics ser-
vices, microbiology and virology services and photographic
equipment. Table 2 describes the postbiopsy sample processing.
The remaining tissue should be fixed in formalin. Table 3
describes the routine stains to be used. Details of transport of
specimens can be found online.
OTHER SOURCES OF LUNG TISSUE
Postmortem and explanted lung tissue should be accessed if at
all possible, and handled in the same way as a lung biopsy. Even
if permission for autopsy is refused, it may be possible to obtain
permission for percutaneous, transthoracic True-cut needle biop-
sies. DNA of the patient and both parents should be stored with
the family’s permission, if this has not already been done.
Another valuable source of tissue is the explanted lungs after
lung transplantation.
THE ROLE OF PEER REVIEW
chILD is a spectrum of very rare conditions, and no centre will
see many cases. The diagnosis may be obvious, as, for example,
a suspected surfactant protein gene mutation when known
disease causing mutations are detected. However, in many cases
the interpretation of CT scans and lung biopsy material is diffi-
cult. We believe that the best practice is to peer review these
cases so that patients have the benefit of a consensus view from
different specialists who can pool and increase their expertise.
This is an integral part of our protocols. In chILD-EU, cases are
peer reviewed at point of diagnosis and revisited at 12 monthly
intervals to gauge the precision of diagnosis and patient
outcome.
PROPOSED TREATMENT PROTOCOLS: THE DELPHI
PROCESS
In the absence of any randomised controlled trial data, a Delphi
process was undertaken to achieve a consensus on treatment
protocols to harmonise treatment approaches. The full details
are given in the online supplementary material. Briefly, we con-
ducted a two-round web-based Delphi consensus of clinicians
caring for chILD. Clinicians were identified from registered
email addresses with national paediatric respiratory society
groups, including the paediatric assembly of the American
Thoracic Society. The questions were derived by the chILD-EU
core management team, with adaptation by the lead representa-
tives for clinicians in North America (Robin Deterding) and
Australia (Adam Jaffe). The survey consisted of a scenario stem
and related questions. All scenarios related to children with
proven or highly suspected ILD. The survey was in English.
Survey 1 consisted of 8 scenario stems with 75 responses
required, survey 2 of 9 lead statements with 11 individual
responses required. Clinicians were asked to score according to
agreement: 1 Strongly Agree; 2 Agree; 3 Neutral; 4 Disagree; 5
Strongly Disagree; 6 Don’t know.
Survey 1 was approached by 173 clinicians. Twenty-nine
responders who provided fewer than 50% of responses were
removed from the analysis. Data is presented from 144 clinician
responders: Australia 14, Canada 3, France 5, Germany 15,
Italy 1, USA 61, UK 37 and other 8. There were 127 respon-
dents to the second round of Delphi. Twelve provided insuffi-
cient data responses (fewer than 50% responses) and so were
removed from the complete analysis. The 115 consultant/attend-
ing pulmonologist respondents contributing to the second
round of Delphi were from the UK (36), USA (30), Germany
(22), Australia (9), France (6), Italy (5), Canada (2) and other
countries (5).
Delphi 1 consisted of four scenarios related to the care of a
patient who was very sick and ventilated or close to ventilation
for whom no specific treatment was known. Delphi 2 provided
statements derived from the consensus of opinion from the first
Delphi round and asked how clinicians viewed the statement.
Options, provided for varying doses and medicines, are sum-
marised as (a) usual practice or (b) could happily use it if it is
the consensus of the Delphi, or (c) not usual practice and would
not wish to use it even if it is the consensus of the Delphi.
In all scenarios, we were clear that the suggested doses should
be considered starting doses and could be changed at the discre-
tion of the treating clinician at any time. The final consensus for
treatment reached is summarised in table 4, and the consensus
for a significant response in table 5.
Table 2 Handling of lung biopsy specimens
Type of
processing Tissue material used Processing procedure Purpose
1 Majority of the sample (about 80%) 4% Formalin For wax blocks and staining studies and storage
2 Several 1–2 mm cuboidal pieces Glutaraldehyde-buffer Electron microscopy, esp Sp mutations
3 10 to 20% of tissue Snap frozen in liquid nitrogen, place
in −80 freezer
Genetic, biochemical studies, conserve RNA and proteins
RNAlater solution Same as snap frozen, except enzyme activity studies; however, more
convenient as can be shipped at room temperature
4 Fresh tissue (can be the remnant on the
proximal side of the staple line)
None Microbiology
Clearly all necessary clinical samples need to be taken before any is allocated for research.
Table 3 Staining of lung biopsy specimens
Stain Purpose
Always: H&E Overview of extent, distribution and nature of
any pathology
Always: Elastic Van Gieson Collagen/pulmonary vasculature
As indicated: CD34 Vascular marker
As indicated: Perls stain Iron-laden macrophages
As indicated: Bombesin Diagnosis of NEHI
As indicated: Periodic Schiff Glycogen-positive cells: PIG
If infection suspected Ziehl–Neelsen, Grocott, others
As indicated:
immunohistochemistry
Langerhans cells (S-100, CD1a)
NEHI, neuroendocrine cell hyperplasia of infancy.
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OTHER POTENTIAL THERAPIES
There is even less evidence for other regimes and no recommen-
dations are made. If there is evidence of systemic disease, and if
cytotoxic or biological therapies are contemplated, it would
usually be wise to involve a paediatric rheumatologist.
MONITORING CHILD
The variety of ChILD diagnoses makes a single common moni-
toring plan of little value. chILD-EU has looked to enable refer-
ence across diagnoses by the development of an observational
trial protocol focused on the first year of diagnosis. Monitoring
is at months 1, 2, 3, 6 and 12 and annually thereafter. Key
observations are clinical (respiratory rate, heart rate, weight,
oxygen saturation in air awake, oxygen saturation including
overnight while asleep and on exercise, evidence of pulmonary
hypertension) and radiological monitoring (chest X-ray at diag-
nosis, 6 and 12 months; CT not recommended, however, if con-
sidered justifiable, a limited cut thin-section HRCT of areas of
interest should provide sufficient information). In older children
spirometry at each observational monitoring visit should be
recorded, with DLCO (pulmonary haemorrhage monitoring)
and body plethysmography recommended as indicated but at
least once per year.
PULMONARY EXACERBATIONS
Acute pulmonary events associated with instability are a charac-
teristic of many chronic diseases. Although recognised, they are
often difficult to define. No definition exists for a pulmonary
exacerbation in chILD and so we have sought, through the
Delphi process and a review of the evidence, to define what is a
clinically significant change in chILD as a first step towards a
definition of a pulmonary exacerbation (table 5). The period of
stability before and between exacerbations must be defined; for
ChILD this is arbitrarily considered to be at least 7 days of sta-
bility at baseline values. More work is ongoing to define the def-
inition of a pulmonary exacerbation and its relationship with
other respiratory events such as upper respiratory tract infection
and aspiration.
SUMMARY AND CONCLUSIONS
We have proposed a sequence of investigations for chILD, and
provided SOPs for performance of these tests. We aim to har-
monise investigation of chILD to facilitate future research; this
manuscript is the framework on which this will be based.
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Heart Rate 10 20 –
Respiratory Rate 5 10 20%
SpO2 5 10 –
Loss of need for
supplemental oxygen
– – Yes
Loss of need for mechanical
ventilation
– – Yes
Conversely, a deterioration of this size would be considered a significant decline.
SpO2, arterial oxygen saturation.
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